When will retatrutide be FDA approved?

Current Regulatory Status

As of April 2026, retatrutide is an investigational drug — not FDA approved, not available by prescription, and not legally available through compounding pharmacies in the United States.

The TRIUMPH Phase 3 Program

Lilly's TRIUMPH program is a series of eight Phase 3 trials that will underpin the retatrutide NDA:

• TRIUMPH-1 — Obesity without diabetes
• TRIUMPH-2 — Obesity with weight-related comorbidities
• TRIUMPH-3 — Obesity with cardiovascular risk
• TRIUMPH-4 — Type 2 diabetes
• TRIUMPH-5 — Obstructive sleep apnea
• TRIUMPH-6 — Knee osteoarthritis
• TRIUMPH-7 — MASH (metabolic-associated steatohepatitis)
• TRIUMPH-8 — Heart failure with preserved ejection fraction

Readouts through 2026 will inform which indications are in the initial NDA filing versus subsequent sNDAs.

Expected Timeline

• Mid-2026: Major TRIUMPH Phase 3 obesity readouts reported
• Q4 2026: Expected NDA submission to FDA
• 2027: FDA review (standard review ~10 months)
• Late 2027: Likely initial FDA approval
• 2028: Commercial availability and insurance coverage expansion

This timeline assumes no FDA delays, no Complete Response Letter, and no additional safety signals. Biotech timelines are notoriously prone to slippage.

What Phase 2 Results Already Show

Phase 2 obesity data (New England Journal of Medicine, 2023) reported mean weight loss of 24.2% over 48 weeks at the 12 mg dose. Phase 3 readouts at higher doses and longer durations are expected to show even greater weight loss — some early reports mention mean losses approaching 28.7%.

Why Retatrutide Matters

Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. This triple mechanism produces larger weight loss than tirzepatide's dual-agonist approach or semaglutide's single GLP-1 activation. If approved, retatrutide will likely set a new standard for obesity pharmacotherapy.

Current Access Paths (Limited)

• Clinical trial enrollment: The TRIUMPH program is still recruiting for some trial arms. Check clinicaltrials.gov for current openings.
• No legitimate compounded retatrutide: Because it is not FDA approved, it cannot be legally compounded for patient use. Vendors selling "compounded retatrutide" are not providing an FDA-regulated product.
• Research-chemical vendors: Many online vendors sell "retatrutide" labeled "research use only." Quality, purity, and actual peptide identity are not assured. Patient safety cannot be guaranteed through these channels.

What About "Compounded Retatrutide" Online?

Operations advertising compounded retatrutide today are misrepresenting the regulatory status. FDA 503A compounding pharmacies can only legally compound drugs that are FDA-approved or on the 503A Bulks List. Retatrutide is neither. Any operation claiming to provide "compounded retatrutide" is either sourcing from gray-market channels, misusing "compounded" terminology, or both. These are not legitimate clinical products.

What Patients Can Do Now

• Optimize current treatment — semaglutide, tirzepatide, or other approved options cover most patients
• Consider clinical trial enrollment if you meet eligibility criteria
• Watch for 2027 approval announcements and commercial launch plans
• Work with a qualified provider on a sustainable obesity management strategy that doesn't depend on unapproved drugs

Reasonable Comparison to Current Options

For context on the rough positioning retatrutide is expected to occupy:

• Semaglutide (Wegovy) — ~15% weight loss
• Tirzepatide (Zepbound) — ~22.5% weight loss
• Retatrutide (projected) — ~24–28% weight loss

For many patients, current options produce clinically meaningful weight loss. Retatrutide will expand the ceiling, not replace these drugs.

See the retatrutide guide, tirzepatide cost, and semaglutide cost.